Viatris (NSDQ:VTRS) announced that the U.S. District Court for the District of Kansas ruled in favor of Mylan in an EpiPen class action.
Mylan, which Pfizer combined with its Upjohn business to form Viatris in November 2020, received a favorable ruling in substantial part that dismissed all of the plaintiffs’ claims under the federal RICO statute, including claims asserted against former Mylan CEO Heather Bresch.
Get the full story at our sister site, Drug Delivery Business News.
The robotics firm Wyzo (Ecublens, Switzerland) has launched what it deems the world’s first pick-and-place sidebot. Supporting pharmaceutical production line applications, the Wyzo robot can work side-by-side with humans without traditional protective barriers.
The robot also supports up to 80 picks per minute.
The Wyzo is also compatible with standard grippers.
The company says that the Wyzo robot occupies one-sixth of the space of a traditional industrial robot. Its footprint is less than 0.5 m2, and the robot measures 1.80 m in height. The small size enables manufacturers to relocate the robot from one workstation to another as needed. Workers can transport it through standard doors or via elevators.
The Wyzo uses sensor technology to monitor nearby human activity. Its software enables it to reduce its operating speed when a human is nearby.
Wyzo also says the robot is easy to program even for operators without prior experience in automa…
RedHill Biopharma Ltd. (Nasdaq: RDHL) announced positive results from a Phase 2 U.S. study involving its opaganib in hospitalized COVID-19 patients with pneumonia.
The study indicated that opaganib reduced the need for supplemental oxygen therapy and an earlier hospital discharge. RedHill also concluded that the drug was well-tolerated based on the placebo-controlled Phase 2 study, which involved 40 patients in the U.S.
The experimental drug inhibits sphingosine kinase-2 (SK2), an enzyme that plays a role in inflammation and replication of some viruses. Opaganib thus has dual antiviral and anti-inflammatory modes of action.
A total of 50% of opaganib recipients could breathe without ventilator support within 14 days of treatment compared to 22% of people in the placebo group.
Some 86.4% of patients receiving opaganib were able to leave the hospital within 14 days compared with 55.6% of placebo recipients.
The study anticipates that th…
The British medtech giant seeks to tap digital health to fuel growth in orthopedics. The Aria Home PT remote physical therapy device is the latest example.
The Aria Home PT [Image courtesy of Smith+Nephew]It’s the size of a small flatscreen TV and shows up at someone’s house before they undergo knee or hip surgery at an ambulatory surgery center, interacting with them throughout the entire episode of care. Think interactive home physical therapy sessions, education, telehealth visits and more — all delivered with the help of a friendly avatar called Aria.That’s the promise that Smith+Nephew (LSE:SN, NYSE:SNN) officials see in their Aria Home PT remote physical therapy device, launched in May as one of the latest additions to the company’s Aria digital care management platform.
“Our goal is to be the fastest-growing, most innovative orthopedic company out there, and our focus on digital health is one of the ways that we’…
The British medtech giant seeks to tap digital health to fuel growth in orthopedics. The Aria Home PT remote physical therapy device is the latest example.
The Aria Home PT [Image courtesy of Smith+Nephew]
It’s the size of a small flatscreen TV and shows up at someone’s house before they undergo knee or hip surgery at an ambulatory surgery center, interacting with them throughout the entire episode of care. Think interactive home physical therapy sessions, education, telehealth visits and more — all delivered with the help of a friendly avatar called Aria.That’s the promise that Smith+Nephew (LSE:SN, NYSE:SNN) officials see in their Aria Home PT remote physical therapy device, launched in May as one of the latest additions to the company’s Aria digital care management platform.
“Our goal is to be the fastest-growing, most innovative orthopedic company out there, and…
Medtech trade group AdvaMed wants the Biden administration to put the transport of medical supplies at the top of its list to address supply chain problems at ports worldwide.
On his first day in office, Biden issued an executive order that promised, in part, to secure the pandemic supply chain and create a U.S. manufacturing base to fill the strategic national stockpile. The stockpile was found to have expired N95 masks and to be generally unprepared for the onslaught of pleas from frontline workers desperate for personal protective equipment (PPE).
Get the full story on our sister site, Medical Design & Outsourcing.
Medical device manufacturers are experiencing unprecedented challenges. With the global pandemic negatively impacting markets, they are under pressure to produce increasingly complex products, quicker and at lower cost.
To remain competitive in this marketplace, manufacturers must move towards smart manufacturing to increase innovation and enhance processes. To take significant, actionable steps in manufacturing and production processes, enterprises must undergo a cultural shift in the way they use data.
Download this white paper on the 4 steps to achieve operational excellence.
if(!gform){document.addEventListener("gform_main_scripts_loaded",function(){gform.scriptsLoaded=!0}),window.addEventListener("DOMContentLoaded",function(){gform.domLoaded=!0});var gform={domLoaded:!1,scriptsLoaded:!1,initializeOnLoaded:function(o){gform.domLoaded&&gform.scriptsLoaded?o():!gform.domLoaded&&gform.scriptsLoaded?window.addEventListener("DOMContentLoaded"…Second Sight Medical Products announced that it plans to offer shares of its common stock in a public offering worth $50 million.
Los Angeles-based Second Sight priced the underwritten public offering of 10 million shares of common stock at a public offering price of $5 per share to yield gross proceeds of $50 million, according to a news release.
Should an overallotment option granted through a 45-day option to purchase up to 1.5 million additional shares be exercised, the proceeds could reach $57.5 million before discounts, commissions and other expenses. All shares are to be sold by Second Sight.
The Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock, solely to cover over-allotments. All of the shares of common stock are being offered by the Company.
Second Sight expects the offering to close on June 25, 2021, after which it plans to use the proceeds for the development of its O…
For the past 15 months, DeviceTalks has connected tens of thousands of medical professionals through a growing series of podcasts and virtual meetings.
Now, we’re pleased to announce we’ll be resuming our in-person meetings in 2022.
DeviceTalks will hold meetings in three of the country’s medical device hubs – Boston, Minneapolis and Silicon Valley. Each DeviceTalks meeting will host workshops and hands-on sessions where innovators, engineers, manufacturers, and other experts can share insights and expertise.
Attendees will also hear from leaders of medtech’s largest medical device companies.
DeviceTalks organizers have connected with industry leaders to assist with content planning and speaker engagement. A sample of the companies expected to assist in our 2022 programs include Abbott, AtriCure, Boston Scientific, Broadview Ventures, Cala Health, Explorer Surgical, Hologic, Intuitive Surgical, Johnson & Johnson, KCK, Mayo Clinic, Medical Alle…
For the past 15 months, DeviceTalks has connected tens of thousands of medical professionals through a growing series of podcasts and virtual meetings.
Now, we’re pleased to announce we’ll be resuming our in-person meetings in 2022.
DeviceTalks will hold meetings in three of the country’s medical device hubs – Boston, Minneapolis and Silicon Valley. Each DeviceTalks meeting will host workshops and hands-on sessions where innovators, engineers, manufacturers, and other experts can share insights and expertise.
Attendees will also hear from leaders of medtech’s largest medical device companies.
DeviceTalks organizers have connected with industry leaders to assist with content planning and speaker engagement. A sample of the companies expected to assist in our 2022 programs include Abbott, AtriCure, Boston Scientific, Broadview Ventures, Cala Health, Explorer Surgical, Hologic, Intuitive Surgical, Johnson & Johnson, KCK, Mayo Clinic, Medical Alle…
Outset Medical (NSDQ:OM) announced today that it appointed Jean-Olivier Racine as its new chief technology officer.
Racine, a veteran of more than two decades in the technology industry, previously worked as the head of engineering and science for Amazon Web Services (AWS) Health AI, where he managed Amazon Comprehend Medical, Amazon HealthLake and more health services in development, according to a news release.
San Jose, Calif.-based Outset said Racine’s new role will have him oversee the strategic advancement of the company’s product technology, amplify the company’s data-driven innovation engine to elevate the patient care experience and drive operating efficiencies for providers.
“Jean-Olivier’s knowledge of the development of high-scale and high-availability services for the storage of health data, such as HealthLake, is critical to the innovation initiatives we intend to pursue in order to empower patients and healthcare provider…
Penumbra (NYSE:PEN) today said its Red 62 reperfusion catheter has received FDA 510(k) clearance.
Alameda, Calif.-based Penumbra designed the catheter to navigate complex distal vessel anatomy and deliver powerful aspiration with its Penumbra Engine to remove blood clots in acute ischemic stroke patients with large vessel occlusions.
Get the full story on our sister site, Medical Tubing + Extrusion.